Joint Formulary & PAD

Bromocriptine - Prevention or Suppression of lactation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Bromocriptine
Indication :
Prevention or Suppression of lactation
Group Name :
Keywords :
Prevention of lactation, lactation suppression
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Bromocriptine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Prevention or Suppression of lactation.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the following place in therapy for cabergoline and bromocriptine:

Suppression of lactation

  • RED traffic light classification for cabergoline - as treatment should be part of obstetric care where necessary
  • Non-Formulary for bromocriptine

For the treatment of hyperprolactinaemic disorders

  • BLUE traffic light classification for initiation by specialists for 1 month before transfer of prescribing responsibilities to primary care
  • Cabergoline 1st line & Bromocriptine 2nd line

For the treatment of drug induced hyperprolactinaemia

  • 1st line - select alternative medicine (to remove cause of drug-induced effect)
  • Non-Formulary for cabergoline and bromocriptine